"I'm wildly bullish, and I may be dead wrong, but I'm wildly bullish."
Geron's Imetelstat has emerged as a potential game-changer in the field of hematological cancers. Despite facing competition from other pharmaceutical companies and safety concerns regarding discontinuation rates, this telomerase inhibitor aims to halt the proliferation of malignant hematopoietic stem cells. Geron is the only company …
In the highly competitive arena of large-cap exchange-traded funds (ETFs), two formidable contenders have emerged: SCHX and VOO. Boasting total assets of over $29B and $264B respectively, these funds have established their credibility and size in the market. With SCHX tracking the Dow Jones US …
Carvana, the online used car marketplace, is facing a significant decline in its stock price amid concerns over its debt restructuring plan. The company's credit rating has been downgraded by S&P Global Ratings, and the proposed debt exchange could potentially be classified as a default …